You see the fact sheet Alimta in the following format: 100 mg powder for a solution for infusion Box of one vial of 100 mg of powder
Therapeutic class: Oncology and Hematology
Presentation: 100 mg Powder for a solution for infusion Box of one vial of 100 mg of powder
Indications Dosage Warnings against Interactions Precautions Side effects
- Malignant pleural mesothelioma:
ALIMTA in mixture with cisplatin is indicated for the healing of patients with malignant pleural mesothelioma whose disease is unrespectable and who have not up to that time received chemotherapy.
- Non-small lung cancer cells:
- ALIMTA in mixture with cisplatin is indicated for patients with non-small cell lung cancer, locally advanced or metastatic, when the histology is predominantly squamous-cell carcinoma.
- ALIMTA is indicated as monotherapy for second-line treatment in patients with non-small cell lung cancer in locally advanced or metastatic, when the histology is not primarily squamous-cell carcinoma.